Clinical Trials
26 trialsNCT04634877 2026-06-05
KEYNOTE-B21
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT07578649 2026-06-04
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
Pfizer
Phase 3 Not yet recruiting
NCT06952504 2026-06-03
TroFuse-033
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07166094 2026-06-02
RAINFOL-03
Genmab
Phase 3 Recruiting
NCT04269200 2026-06-01
DUO-E
AstraZeneca
Phase 3 Active not recruiting
NCT05611931 2026-05-29
XPORT-EC-042
Karyopharm Therapeutics Inc
Phase 3 Active not recruiting
NCT07022483 2026-05-28
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Daiichi Sankyo
Phase 3 Recruiting
NCT07286331 2026-05-27
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
GlaxoSmithKline
Phase 3 Not yet recruiting
NCT06340568 2026-05-20
Fern-EC-01
BioNTech SE
Phase 3 Recruiting
NCT07044336 2026-05-20
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
AstraZeneca
Phase 3 Recruiting
NCT06989112 2026-05-06
DE-01
AstraZeneca
Phase 3 Recruiting
NCT05173987 2026-05-05
KEYNOTE-C93
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06746116 2026-04-16
DUoENDE
AstraZeneca
Phase 3 Active not recruiting
NCT03555422 2026-04-13
ENGOT-EN5
Karyopharm Therapeutics Inc
Phase 3 Completed
NCT06132958 2026-04-03
TroFuse-005
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03517449 2026-03-19
MK-3475-775
Eisai Inc.
Phase 3 Completed
NCT03884101 2026-02-02
LEAP-001
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06486441 2026-01-15
ASCENT-GYN-01
Gilead Sciences
Phase 3 Active not recruiting
NCT04865289 2025-12-02
LEAP-001
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06584032 2025-01-07
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Hutchmed
Phase 3 Recruiting
NCT06475599 2024-06-27
Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT02584478 2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3 Unknown
NCT05712941 2023-11-03
Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer
EQRx International, Inc.
Phase 3 Withdrawn
NCT01767155 2018-07-31
ZoptEC
AEterna Zentaris
Phase 3 Completed
NCT00883116 2017-03-09
IXAMPLE2
R-Pharm
Phase 3 Terminated
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed